A Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0200390 In Six Healthy Male Volunteers

Phase 1

Completed

• Conditions: Insomnia
• Interventions: Drug: PD 0200390

• Registration Number: NCT00722306
• Lead Sponsor: Pfizer

Brief Summary

To determine the mass balance of PD 0200390

Detailed Description

Not available

Study Timeline

• Study Start: 2008-05
• Primary Completion: 2008-05
• Study Completion: 2008-05
• Study First Submitted: 2008-07-23
• Study First Submitted QC: 2008-07-24
• Study First Posted: 2008-07-25
• Status Verified: 2011-02
• Last Update Submitted: 2011-02-03
• Last Update Posted: 2011-02-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

• Healthy

Read More

Exclusion Criteria

• unhealthy, or concomitant meds

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
A425	PD 0200390	A425 Treated

Primary Outcome Measures

Name	Time	Method
Radioactivity parameters in plasma and whole blood - Cmax , Tmax , AUCinf, AUClast, t1/2, CL/F and V/F and Total 14C data in blood, urine and feces	2 days

Secondary Outcome Measures

Name	Time	Method
% urinary recovery	2 days

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇺🇸 New Haven, Connecticut, United States